Status:
TERMINATED
An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Deep Tissue Infection Due To Candida
Lead Sponsor:
Pfizer
Conditions:
Candidiasis
Fungemia
Eligibility:
All Genders
16+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to gather information on the use of anidulafungin for the treatment of serious Candida infection. It is expected that anidulafungin will be at least as safe and as effecti...
Eligibility Criteria
Inclusion
- Diagnosis of deep tissue Candida infection, defined as growth of Candida sp. from a culture specimen obtained from a normally sterile site accompanied by signs and symptoms of infection.
- Male or female ≥ 16 years of age.
- Expected hospitalization for at least fourteen (14) days.
Exclusion
- Pregnancy or breast feeding or planning to become pregnant during the study.
- Recent treatment with one of the study drugs over the last 30 days.
- Allergy to either study drug or to this class of drugs.
- Significant liver dysfunction.
- Suspected Candida osteomyelitis, endocarditis, meningitis or any other infections of the central nervous system.
Key Trial Info
Start Date :
April 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2012
Estimated Enrollment :
41 Patients enrolled
Trial Details
Trial ID
NCT00805740
Start Date
April 1 2009
End Date
June 1 2012
Last Update
August 1 2013
Active Locations (18)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Newark, Delaware, United States, 19713
2
Pfizer Investigational Site
Newark, Delaware, United States, 19718
3
Pfizer Investigational Site
Wilmington, Delaware, United States, 19801
4
Pfizer Investigational Site
Detroit, Michigan, United States, 48202